Med Pharma Service GmbH
Pharmaceutical Companies · Berlin
Med Pharma Service GmbH is a pharmaceutical company based in Berlin, Berlin, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Med Pharma Service GmbH Address & Contact
Med Pharma Service GmbH Overview
Med Pharma Service GmbH in Berlin is a dynamic German pharmaceutical company that focuses on pharmaceutical services and the distribution of medicinal products. Founded in a city that is considered a center for research, development, and regulation in the healthcare sector, Med Pharma Service takes advantage of Berlin's infrastructure for its comprehensive pharmaceutical activities. The company aims to provide high-quality services and products that meet the high standards of the German healthcare market.
Field of Activity and Products
Med Pharma Service offers a variety of pharmaceutical services specifically aimed at drug manufacturers and importers. The field of activity includes the following core areas:
- Regulatory Support: The company assists its clients in compliance with regulatory requirements and provides advice in all phases of drug development.
- Pharmacovigilance: Med Pharma Service monitors the safety of medicinal products and collects data on side effects to ensure pharmaceutical safety.
- Distribution: The company distributes human medicinal products from various therapeutic areas, including oncology, cardiology, and neurology, ensuring that these products meet strict safety and quality standards.
The company's portfolio includes products from different therapeutic areas that are marketed in Germany. Through strategic partnerships with manufacturers, Med Pharma Service can offer a wide range of medicinal products that are innovative and effective. Close collaboration with research institutions plays a central role in this.
Regulatory Classification
Med Pharma Service GmbH is committed to complying with all relevant laws and regulations applicable to pharmaceutical services and the distribution of medicinal products in Germany. This includes adherence to the regulations of the Ministry of Health, the Federal Institute for Drugs and Medical Devices (BfArM), and the Paul Ehrlich Institute (PEI). An important aspect of regulatory activity is the continuous training of employees to ensure that all legal changes are implemented promptly.
Location Berlin
Berlin as the federal capital plays a significant role for Med Pharma Service. The city is not only the seat of federal authorities but also a center for medical research and innovation. Due to its proximity to renowned institutions such as Charité and the Berlin Institute of Health (BIH), Med Pharma Service has access to a broad network of researchers and other companies. This facilitates the exchange of knowledge and technologies and promotes the development of new medicinal products.
Another advantage of the Berlin location is the pronounced biotech and pharmaceutical industry. Numerous companies, from start-ups to established firms, foster a dynamic culture of innovation that Med Pharma Service can leverage through collaborations and networking. This special position in the region also offers the workforce excellent career opportunities in a highly specialized professional field.
Special Features and Future Outlook
Med Pharma Service GmbH positions itself as a flexible partner for clients who rely on the expertise of a nationally active, yet location-bound service provider. With a focus on sustainability and social responsibility, the company is committed to developing environmentally friendly medicinal products and/or manufacturing processes. In the near future, Med Pharma Service plans to expand its product lines as well as integrate new digital solutions to optimize processes and increase efficiency in drug supply.
In summary, Med Pharma Service GmbH is not only an important player in the German pharmaceutical sector but also significantly contributes to the further development of the industry. With a combination of regulatory knowledge, a diverse product range, and the advantages of the Berlin location, the company is well positioned to meet future challenges.
More information: Pharmaceutical companies in Berlin or all pharmaceutical companies in Germany on Sanoliste.
```Frequently asked questions about Med Pharma Service GmbH
What does Med Pharma Service GmbH do?
Med Pharma Service GmbH stellt probiotische Milchsäurebakterien her and aboutnimmt for Pharmaundernehmen the Erstellung of Produktprofilen and wissenschaftlichen Gutachten, macht Stabilitätsprüfungspläne and mikrobiologische Untersuchungen. Zudem aboutnehmen sie for the medicinesherstellung Lohnherstellung, Konfektionierung and Logisik.
More Pharmaceutical Companies in Berlin
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.